Robert S Plumb

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3056527/publications.pdf Version: 2024-02-01

		41344	34986
132	10,488	49	98
papers	citations	h-index	g-index
133	133	133	9289
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Access to the Phospho-proteome via the Mitigation of Peptide-Metal Interactions. Journal of Chromatography A, 2022, 1673, 463024.	3.7	6
2	Application of hybrid surface technology for improving sensitivity and peak shape of phosphorylated lipids such as phosphatidic acid and phosphatidylserine. Journal of Chromatography A, 2022, 1669, 462921.	3.7	7
3	High Throughput UHPLC-MS-Based Lipidomics Using Vacuum Jacketed Columns. Journal of Proteome Research, 2022, 21, 691-701.	3.7	4
4	High performance Reversed-Phase Thin-Layer Chromatography-Desorption electrospray ionisation - time of flight high resolution mass spectrometric detection and imaging (HPTLC/DESI/ToFMS) of phytoecdysteroids. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2022, 1200, 123265.	2.3	7
5	Rapid determination of the pharmacokinetics and metabolic fate of gefitinib in the mouse using a combination of UPLC/MS/MS, UPLC/QToF/MS, and ion mobility (IM)-enabled UPLC/QToF/MS. Xenobiotica, 2021, 51, 434-446.	1.1	8
6	Use of Cyclic Ion Mobility Spectrometry (cIM)-Mass Spectrometry to Study the Intramolecular Transacylation of Diclofenac Acyl Glucuronide. Analytical Chemistry, 2021, 93, 7413-7421.	6.5	13
7	Hybrid organic/inorganic hybrid surface technology for increasing the performance of LC/MS(MS)-based drug metabolite identification studies: Application to gefitinib and metabolites in mouse plasma and urine. Journal of Pharmaceutical and Biomedical Analysis, 2021, 200, 114076.	2.8	6
8	The Pharmacometabodynamics of Gefitinib after Intravenous Administration to Mice: A Preliminary UPLC–IM–MS Study. Metabolites, 2021, 11, 379.	2.9	6
9	High-Throughput UHPLC/MS/MS-Based Metabolic Profiling Using a Vacuum Jacketed Column. Analytical Chemistry, 2021, 93, 10644-10652.	6.5	10
10	Proteomic consequences of the deletion of cytochrome P450 (CYP450) reductase in mice. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1179, 122803.	2.3	1
11	Improving LC/MS/MS-based bioanalytical method performance and sensitivity via a hybrid surface barrier to mitigate analyte – Metal surface interactions. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1179, 122825.	2.3	8
12	Cognitive analysis of metabolomics data for systems biology. Nature Protocols, 2021, 16, 1376-1418.	12.0	13
13	High-Throughput Microbore Ultrahigh-Performance Liquid Chromatography-Ion Mobility-Enabled-Mass Spectrometry-Based Proteomics Methodology for the Exploratory Analysis of Serum Samples from Large Cohort Studies. Journal of Proteome Research, 2021, 20, 1705-1715.	3.7	9
14	Rapid profiling method for the analysis of lipids in human plasma using ion mobility enabled-reversed phase-ultra high performance liquid chromatography/mass spectrometry. Journal of Chromatography A, 2020, 1611, 460597.	3.7	21
15	Liquid chromatographic methods combined with mass spectrometry in metabolomics. , 2020, , 149-169.		2
16	High fat diet causes distinct aberrations in the testicular proteome. International Journal of Obesity, 2020, 44, 1958-1969.	3.4	17
17	The analysis of acetaminophen (paracetamol) and seven metabolites in rat, pig and human plasma by U(H)PLC–MS. Bioanalysis, 2020, 12, 485-500.	1.5	3
18	Metabolic Phenotyping Using UPLC–MS and Rapid Microbore UPLC–IM–MS: Determination of the Effect of Different Dietary Regimes on the Urinary Metabolome of the Rat. Chromatographia, 2020, 83, 853-861.	1.3	6

#	Article	IF	CITATIONS
19	UHPLC-MS-Based Lipidomic and Metabonomic Investigation of the Metabolic Phenotypes of Wild Type and Hepatic CYP Reductase Null (HRN) Mice. Journal of Pharmaceutical and Biomedical Analysis, 2020, 186, 113318.	2.8	2
20	High Performance Thin-Layer Chromatography of Plant Ecdysteroids Coupled with Desorption Electrospray Ionisation–Ion Mobility–Time of Flight High Resolution Mass Spectrometry (HPTLC/DESI/IM/ToFMS). Chromatographia, 2020, 83, 1029-1035.	1.3	12
21	Chemical profiling and characterization of phenolic acids, flavonoids, terpene glycosides from Vangueria agrestis using ultraâ€highâ€performance liquid chromatography/ion mobility quadrupole timeâ€ofâ€flight mass spectrometry and metabolomics approach. Biomedical Chromatography, 2020, 34, e4840.	1.7	8
22	Liquid chromatography-ion mobility-high resolution mass spectrometry for analysis of pollutants in indoor dust: Identification and predictive capabilities. Analytica Chimica Acta, 2020, 1125, 29-40.	5.4	25
23	Estrogen accelerates heart regeneration by promoting the inflammatory response in zebrafish. Journal of Endocrinology, 2020, 245, 39-51.	2.6	25
24	Application of a Novel Mass Spectral Data Acquisition Approach to Lipidomic Analysis of Liver Extracts from Sitaxentan-Treated Liver-Humanized PXB Mice. Journal of Proteome Research, 2019, 18, 4055-4064.	3.7	11
25	A comparison of collision cross section values obtained via travelling wave ion mobility-mass spectrometry and ultra high performance liquid chromatography-ion mobility-mass spectrometry: Application to the characterisation of metabolites in rat urine. Journal of Chromatography A, 2019, 1602. 386-396.	3.7	34
26	Analysis of hexafluoropropylene oxide-dimer acid (HFPO-DA) by liquid chromatography-mass spectrometry (LC-MS): Review of current approaches and environmental levels. TrAC - Trends in Analytical Chemistry, 2019, 118, 828-839.	11.4	52
27	Development of a rapid profiling method for the analysis of polar analytes in urine using HILIC–MS and ion mobility enabled HILIC–MS. Metabolomics, 2019, 15, 17.	3.0	57
28	Ultrahigh-Performance Liquid Chromatography Tandem Mass Spectrometry with Electrospray Ionization Quantification of Tryptophan Metabolites and Markers of Gut Health in Serum and Plasma—Application to Clinical and Epidemiology Cohorts. Analytical Chemistry, 2019, 91, 5207-5216.	6.5	72
29	Untargeted LC/MS-based metabolic phenotyping (metabonomics/metabolomics): The state of the art. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1117, 136-147.	2.3	106
30	The metabolic fate and effects of 2-Bromophenol in male Sprague–Dawley rats. Xenobiotica, 2019, 49, 1352-1359.	1.1	2
31	A validated UPLC-MS/MS assay for the quantification of amino acids and biogenic amines in rat urine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1106-1107, 50-57.	2.3	8
32	Supercritical Fluid Chromatography for Metabolic Phenotyping: Potential and Applications. , 2019, , 205-217.		0
33	Capillary ultra performance liquid chromatography–tandem mass spectrometry analysis of tienilic acid metabolites in urine following intravenous administration to the rat. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1087-1088, 142-148.	2.3	4
34	High-Speed Quantitative UPLC-MS Analysis of Multiple Amines in Human Plasma and Serum via Precolumn Derivatization with 6-Aminoquinolyl- <i>N</i> -hydroxysuccinimidyl Carbamate: Application to Acetaminophen-Induced Liver Failure. Analytical Chemistry, 2017, 89, 2478-2487.	6.5	78
35	Ion mobility spectrometry combined with ultra performance liquid chromatography/mass spectrometry for metabolic phenotyping of urine: Effects of column length, gradient duration and ion mobility spectrometry on metabolite detection. Analytica Chimica Acta, 2017, 982, 1-8.	5.4	53
36	Themed issue on â€~emerging technologies in mass spectrometry'. Bioanalysis, 2017, 9, 1617-1618.	1.5	0

#	Article	IF	CITATIONS
37	Metabolic phenotyping (metabonomics/metabolomics) by liquid chromatography-mass spectrometry. , 2017, , 245-265.		Ο
38	Analysis of polar urinary metabolites for metabolic phenotyping using supercritical fluid chromatography and mass spectrometry. Journal of Chromatography A, 2016, 1449, 141-155.	3.7	60
39	Development of a Rapid Microbore Metabolic Profiling Ultraperformance Liquid Chromatography–Mass Spectrometry Approach for High-Throughput Phenotyping Studies. Analytical Chemistry, 2016, 88, 5742-5751.	6.5	39
40	A method for the direct injection and analysis of small volume human blood spots and plasma extracts containing high concentrations of organic solvents using revered-phase 2D UPLC/MS. Analyst, The, 2015, 140, 1921-1931.	3.5	8
41	Ion Mobility-Derived Collision Cross Section As an Additional Measure for Lipid Fingerprinting and Identification. Analytical Chemistry, 2015, 87, 1137-1144.	6.5	245
42	Tetrahydrobiopterin and alkylglycerol monooxygenase substantially alter the murine macrophage lipidome. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2431-2436.	7.1	50
43	Identification of a novel human circulating metabolite of tenofovir disoproxil fumarate with LC–MS/MS. Bioanalysis, 2015, 7, 643-652.	1.5	7
44	An integrated ceramic, micro-fluidic device for the LC/MS/MS analysis of pharmaceuticals in plasma. Analyst, The, 2015, 140, 5546-5556.	3.5	15
45	Practical applications of integrated microfluidics for peptide quantification. Bioanalysis, 2015, 7, 857-867.	1.5	10
46	Integration of microfluidic LC with HRMS for the analysis of analytes in biofluids: past, present and future. Bioanalysis, 2015, 7, 1397-1411.	1.5	10
47	High-Throughput Microbore UPLC–MS Metabolic Phenotyping of Urine for Large-Scale Epidemiology Studies. Journal of Proteome Research, 2015, 14, 2714-2721.	3.7	33
48	Advances in liquid chromatography coupled to mass spectrometry for metabolic phenotyping. TrAC - Trends in Analytical Chemistry, 2014, 61, 181-191.	11.4	53
49	Ultra high resolution SFC–MS as a high throughput platform for metabolic phenotyping: Application to metabolic profiling of rat and dog bile. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 966, 200-207.	2.3	41
50	Current practice of liquid chromatography–mass spectrometry in metabolomics and metabonomics. Journal of Pharmaceutical and Biomedical Analysis, 2014, 87, 12-25.	2.8	348
51	Metabolic Phenotyping Reveals a Lipid Mediator Response to Ionizing Radiation. Journal of Proteome Research, 2014, 13, 4143-4154.	3.7	62
52	Global metabolic profiling of animal and human tissues via UPLC-MS. Nature Protocols, 2013, 8, 17-32.	12.0	774
53	Comparison of reversed-phase and hydrophilic interaction liquid chromatography for the quantification of ephedrines using medium-resolution accurate mass spectrometry. Journal of Chromatography A, 2013, 1289, 37-46.	3.7	43
54	Liquid Chromatographic Methods Combined with Mass Spectrometry inÂMetabolomics. , 2013, , 145-161.		2

4

#	Article	IF	CITATIONS
55	Liquid Chromatographic Techniques in Metabolomics. RSC Chromatography Monographs, 2013, , 64-86.	0.1	2
56	Investigation of microbore UPLC and nontraditional mobile phase compositions for bioanalytical LC–MS/MS. Bioanalysis, 2012, 4, 1287-1297.	1.5	25
57	Investigation of basic mobile phases with positive ESI LC–MS for metabonomics studies. Bioanalysis, 2012, 4, 2833-2842.	1.5	6
58	Intra- and Interlaboratory Reproducibility of Ultra Performance Liquid Chromatography–Time-of-Flight Mass Spectrometry for Urinary Metabolic Profiling. Analytical Chemistry, 2012, 84, 2424-2432.	6.5	44
59	Comparison of the quantification of a therapeutic protein using nominal and accurate mass MS/MS. Bioanalysis, 2012, 4, 605-615.	1.5	34
60	Comparison of reversed-phase and hydrophilic interaction liquid chromatography for the separation of ephedrines. Journal of Chromatography A, 2012, 1228, 329-337.	3.7	41
61	Comprehensive investigation of the influence of acidic, basic, and organic mobile phase compositions on bioanalytical assay sensitivity in positive ESI mode LC/MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2012, 59, 138-150.	2.8	43
62	HILIC-UPLC-MS for Exploratory Urinary Metabolic Profiling in Toxicological Studies. Analytical Chemistry, 2011, 83, 382-390.	6.5	135
63	Systematic evaluation of acetone and acetonitrile for use in hydrophilic interaction liquid chromatography coupled with electrospray ionization mass spectrometry of basic small molecules. Rapid Communications in Mass Spectrometry, 2011, 25, 3666-3674.	1.5	12
64	Rapid analysis of dried blood spot samples with sub-2-µm LC–MS/MS. Bioanalysis, 2011, 3, 411-420.	1.5	21
65	Addressing the challenge of limited sample volumes in <i>in vitro</i> studies with capillary-scale microfluidic LC–MS/MS. Bioanalysis, 2011, 3, 873-882.	1.5	16
66	Rapid detection and identification of counterfeit of adulterated products of synthetic phosphodiesterase typeâ€5 inhibitors with an atmospheric solids analysis probe. Drug Testing and Analysis, 2010, 2, 45-50.	2.6	17
67	Development of a high sensitivity bioanalytical method for alprazolam using ultraâ€perforâ€mance liquid chromatography/tandem mass spectrometry. Drug Testing and Analysis, 2010, 2, 11-18.	2.6	6
68	A rapid ultraâ€performance liquid chromatography/tandem mass spectrometric methodology for the <i>in vitro</i> analysis of Pooled and Cocktail cytochrome P450 assays. Rapid Communications in Mass Spectrometry, 2010, 24, 147-154.	1.5	24
69	Global metabolic profiling procedures for urine using UPLC–MS. Nature Protocols, 2010, 5, 1005-1018.	12.0	867
70	A novel LC–MS approach for the detection of metabolites in DMPK studies. Bioanalysis, 2010, 2, 1767-1778.	1.5	13
71	Ultra Performance Liquid Chromatography-Mass Spectrometry Profiling of Bile Acid Metabolites in Biofluids: Application to Experimental Toxicology Studies. Analytical Chemistry, 2010, 82, 5282-5289.	6.5	89
72	Use of an Atmospheric Solids Analysis Probe (ASAP) for High Throughput Screening of Biological Fluids: Preliminary Applications on Urine and Bile. Journal of Proteome Research, 2010, 9, 3590-3597.	3.7	26

#	Article	IF	CITATIONS
73	Application of Ultra Performance Liquid Chromatographyâ^'Mass Spectrometry to Profiling Rat and Dog Bile. Journal of Proteome Research, 2009, 8, 2495-2500.	3.7	62
74	Sub one minute inhibition assays for the major cytochrome P450 enzymes utilizing ultraâ€performance liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2008, 22, 1345-1350.	1.5	22
75	Addressing the analytical throughput challenges in ADME screening using rapid ultraâ€performance liquid chromatography/tandem mass spectrometry methodologies. Rapid Communications in Mass Spectrometry, 2008, 22, 2139-2152.	1.5	32
76	Ultraâ€performance LC/TOF MS analysis of medicinal <i>Panax</i> herbs for metabolomic research. Journal of Separation Science, 2008, 31, 1015-1026.	2.5	161
77	1H NMR and UPLC-MSE Statistical Heterospectroscopy: Characterization of Drug Metabolites (Xenometabolome) in Epidemiological Studies. Analytical Chemistry, 2008, 80, 6835-6844.	6.5	74
78	A Rapid Simple Approach to Screening Pharmaceutical Products Using Ultra-Performance LC Coupled to Time-of-Flight Mass Spectrometry and Pattern Recognition. Journal of Chromatographic Science, 2008, 46, 193-198.	1.4	24
79	Novel Application of Reversed-Phase UPLC-oaTOF-MS for Lipid Analysis in Complex Biological Mixtures: A New Tool for Lipidomics. Journal of Proteome Research, 2007, 6, 552-558.	3.7	156
80	The application of small porous particles, high temperatures, and high pressures to generate very high resolution LC and LC/MS separations. Journal of Separation Science, 2007, 30, 1158-1166.	2.5	62
81	The rapid detection and identification of the impurities of simvastatin using high resolution sub 2 μm particle LC coupled to hybrid quadrupole time of flight MS operating with alternating high–low collision energy. Journal of Separation Science, 2007, 30, 2666-2675.	2.5	14
82	A gender-specific discriminator in Sprague–Dawley rat urine: The deployment of a metabolic profiling strategy for biomarker discovery and identification. Analytical Biochemistry, 2007, 362, 182-192.	2.4	46
83	Ultra-performance liquid chromatography/tandem mass spectrometric quantification of structurally diverse drug mixtures using an ESI-APCI multimode ionization source. Rapid Communications in Mass Spectrometry, 2007, 21, 893-902.	1.5	38
84	A metabonomic study of strain- and age-related differences in the Zucker rat. Rapid Communications in Mass Spectrometry, 2007, 21, 2039-2045.	1.5	42
85	Highâ€temperature ultraâ€performance liquid chromatography coupled to hybrid quadrupole timeâ€ofâ€flight mass spectrometry applied to ibuprofen metabolites in human urine. Rapid Communications in Mass Spectrometry, 2007, 21, 4079-4085.	1.5	17
86	The application of microbore UPLC/oa-TOF-MS and 1H NMR spectroscopy to the metabonomic analysis of rat urine following the intravenous administration of pravastatin. Journal of Pharmaceutical and Biomedical Analysis, 2007, 44, 845-852.	2.8	53
87	A multi-analytical platform approach to the metabonomic analysis of plasma from normal and zucker (fa/fa) obese rats. Molecular BioSystems, 2006, 2, 174.	2.9	135
88	A pragmatic and readily implemented quality control strategy for HPLC-MS and GC-MS-based metabonomic analysis. Analyst, The, 2006, 131, 1075.	3.5	498
89	Statistical Heterospectroscopy, an Approach to the Integrated Analysis of NMR and UPLC-MS Data Sets: Application in Metabonomic Toxicology Studies. Analytical Chemistry, 2006, 78, 363-371.	6.5	330
90	Generation of Ultrahigh Peak Capacity LC Separations via Elevated Temperatures and High Linear Mobile-Phase Velocities. Analytical Chemistry, 2006, 78, 7278-7283.	6.5	74

#	Article	IF	CITATIONS
91	UPLC/MSE; a new approach for generating molecular fragment information for biomarker structure elucidation. Rapid Communications in Mass Spectrometry, 2006, 20, 1989-1994.	1.5	434
92	UPLC/MSE; a new approach for generating molecular fragment information for biomarker structure elucidation. Rapid Communications in Mass Spectrometry, 2006, 20, 2234-2234.	1.5	13
93	The detection of phenotypic differences in the metabolic plasma profile of three strains of Zucker rats at 20 weeks of age using ultra-performance liquid chromatography/orthogonal acceleration time-of-flight mass spectrometry. Rapid Communications in Mass Spectrometry, 2006, 20, 2800-2806.	1.5	64
94	Statistical Search Space Reduction and Two-Dimensional Data Display Approaches for UPLCâ [^] MS in Biomarker Discovery and Pathway Analysis. Analytical Chemistry, 2006, 78, 4398-4408.	6.5	52
95	The application of sub-2-î¼m particle liquid chromatography-operated high mobile linear velocities coupled to orthogonal accelerated time-of-flight mass spectrometry for the analysis of ranitidine and its impurities. Journal of Separation Science, 2006, 29, 2409-2420.	2.5	18
96	A combined 1H NMR and HPLC–MS-based metabonomic study of urine from obese (fa/fa) Zucker and normal Wistar-derived rats. Journal of Pharmaceutical and Biomedical Analysis, 2005, 38, 465-471.	2.8	109
97	Investigating the human metabolism of acetaminophen using UPLC and exact mass oa-TOF MS. Journal of Pharmaceutical and Biomedical Analysis, 2005, 39, 805-810.	2.8	103
98	HPLC-MS-based methods for the study of metabonomics. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 817, 67-76.	2.3	404
99	Metabonomic Studies Comparing Capillary and Conventional HPLC-oa-TOF MS for the Analysis of Urine from Zucker Obese Rats. Chromatographia, 2005, 61, 375-380.	1.3	34
100	Summary recommendations for standardization and reporting of metabolic analyses. Nature Biotechnology, 2005, 23, 833-838.	17.5	261
101	A high-throughput liquid chromatography/tandem mass spectrometry method for screening glutathione conjugates using exact mass neutral loss acquisition. Rapid Communications in Mass Spectrometry, 2005, 19, 798-804.	1.5	103
102	Increasing throughput and information content forin vitro drug metabolism experiments using ultra-performance liquid chromatography coupled to a quadrupole time-of-flight mass spectrometer. Rapid Communications in Mass Spectrometry, 2005, 19, 843-848.	1.5	186
103	A rapid screening approach to metabonomics using UPLC and oa-TOF mass spectrometry: application to age, gender and diurnal variation in normal/Zucker obese rats and black, white and nude mice. Analyst, The, 2005, 130, 844.	3.5	214
104	Advancing LC Performance with Smaller Particles and Higher Pressure. Analytical Chemistry, 2005, 77, 460 A-467 A.	6.5	284
105	High Resolution "Ultra Performance―Liquid Chromatography Coupled to oa-TOF Mass Spectrometry as a Tool for Differential Metabolic Pathway Profiling in Functional Genomic Studies. Journal of Proteome Research, 2005, 4, 591-598.	3.7	423
106	Extraction, interpretation and validation of information for comparing samples in metabolic LC/MS data sets. Analyst, The, 2005, 130, 701-707.	3.5	114
107	Ultra-performance liquid chromatography coupled to quadrupole-orthogonal time-of-flight mass spectrometry. Rapid Communications in Mass Spectrometry, 2004, 18, 2331-2337.	1.5	319
108	Use of liquid chromatography/time-of-flight mass spectrometry and multivariate statistical analysis shows promise for the detection of drug metabolites in biological fluids. Rapid Communications in Mass Spectrometry, 2003, 17, 2632-2638.	1.5	189

#	Article	IF	CITATIONS
109	Metabonomic analysis of mouse urine by liquid-chromatography-time of flight mass spectrometry (LC-TOFMS): detection of strain, diurnal and gender differences. Analyst, The, 2003, 128, 819.	3.5	145
110	N-Oglucuronidation: a major human metabolic pathway in the elimination of two novel anticonvulsant drug candidates. Xenobiotica, 2002, 32, 29-43.	1.1	15
111	The potential of serially coupled alkyl-bonded silica monolithic columns for high resolution separations of pharmaceutical compounds in biological fluids. Chromatographia, 2002, 55, 177-184.	1.3	19
112	Multidimensional chromatography coupled to electrospray ionization time-of-flight mass spectrometry as an alternative to two-dimensional gels for the identification and analysis of complex mixtures of intact proteins. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 782, 267-289.	2.3	67
113	Metabonomics: the use of electrospray mass spectrometry coupled to reversed-phase liquid chromatography shows potential for the screening of rat urine in drug development. Rapid Communications in Mass Spectrometry, 2002, 16, 1991-1996.	1.5	202
114	Quantitative analysis of pharmaceuticals in biological fluids using high-performance liquid chromatography coupled to mass spectrometry: a review. Xenobiotica, 2001, 31, 599-617.	1.1	51
115	Determination of 4-hydroxytamoxifen in mouse plasma in the?pg/mL range by gradient capillary liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2001, 15, 297-303.	1.5	21
116	Direct analysis of pharmaceutical compounds in human plasma with chromatographic resolution using an alkyl-bonded silica rod column. Rapid Communications in Mass Spectrometry, 2001, 15, 986-993.	1.5	77
117	Direct analysis of a polar pharmaceutical compound in plasma using ultra-high flow rate liquid chromatography/mass spectrometry with a mixed-mode column. Rapid Communications in Mass Spectrometry, 2001, 15, 2526-2529.	1.5	6
118	Use of monolithic silica columns to increase analytical throughput for metabolite identification by liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2001, 15, 152-158.	1.5	67
119	Parallel ultra-high flow rate liquid chromatography with mass spectrometric detection using a multiplex electrospray source for direct, sensitive determination of pharmaceuticals in plasma at extremely high throughput. Rapid Communications in Mass Spectrometry, 2000, 14, 2039-2045.	1.5	89
120	Urinary metabolites of a novel quinoxaline non-nucleoside reverse transcriptase inhibitor in rabbit, mouse and human: identification of fluorine NIH shift metabolites using NMR and tandem MS. Xenobiotica, 2000, 30, 407-426.	1.1	33
121	Urinary metabolites of a novel quinoxaline non-nucleoside reverse transcriptase inhibitor in dog, cynomolgus monkey and mini-pig. Xenobiotica, 1999, 29, 957-967.	1.1	8
122	The rapid identification of drug metabolites using capillary liquid chromatography coupled to an ion trap mass spectrometer. , 1999, 13, 456-463.		40
123	The use of preparative high performance liquid chromatography with tandem mass spectrometric directed fraction collection for the isolation and characterisation of drug metabolites in urine by nuclear magnetic resonance spectroscopy and liquid chromatography/sequential mass spectrometry., 1999, 13, 845-854.		21
124	The application of fast gradient capillary liquid chromatography/mass spectrometry to the analysis of pharmaceuticals in biofluids. , 1999, 13, 865-872.		14
125	Tandem mass spectrometry linked fraction collection for the isolation of drug metabolites from biological matrices. Rapid Communications in Mass Spectrometry, 1999, 13, 886-894.	1.5	18
126	Ultra-high flow rate capillary liquid chromatography with mass spectrometric detection for the direct analysis of pharmaceuticals in plasma at sub-nanogram per millilitre concentrations. , 1999, 13, 1657-1662.		46

#	Article	IF	CITATIONS
127	The use of capillary high performance liquid chromatography with electrospray mass spectrometry for the analysis of small volume blood samples from serially bled mice to determine the pharmacokinetics of early discovery compounds. Rapid Communications in Mass Spectrometry, 1999, 13, 2366-2375.	1.5	25
128	Optimisation and routine use of generic ultra-high flow-rate liquid chromatography with mass spectrometric detection for the direct on-line analysis of pharmaceuticals in plasma. Journal of Chromatography A, 1998, 828, 199-207.	3.7	85
129	Application of a generic fast gradient liquid chromatography tandem mass spectrometry method for the analysis of cytochrome P450 probe substrates. , 1998, 12, 217-224.		95
130	A rapid and efficient approach to metabolite identification using nuclear magnetic resonance spectroscopy, liquid chromatography/mass spectrometry and liquid chromatography/nuclear magnetic resonance spectroscopy/sequential mass spectrometry. Rapid Communications in Mass Spectrometry, 1998, 12, 2023-2030.	1.5	40
131	Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. British Journal of Clinical Pharmacology, 1998, 46, 21-27.	2.4	62
132	The use of turbulent flow chromatography/mass spectrometry for the rapid, direct analysis of a novel pharmaceutical compound in plasma. , 1997, 11, 1953-1958.		158